Introduction
The protooncogene ras encodes a guanine nucleotidebinding GTPase (p21 ras ) that relays extracellular growth and/or differentiation signals to the nucleus, thereby regulating mammalian cell growth. Currently, four ras isoforms (H-ras, N-ras, K-ras4A, K-ras4B) and two ras-related proteins (R-ras and TC21) have been identified, all with similar functions. Each Ras protein (p21 ras ) alternates between a GTP-bound active state and a GDP-bound inactive state. Activating ras point mutations, invariably found in the GTP binding regions, produce an activated, injections (2 × 10 9 p.f.u.) at 7 days after tumor induction. Preexisting tumor growth was reduced by 39% by a single intratumoral injection. Repeat injections (three or five KRbz-ADVintratumoral injections at 2 × 10 9 p.f.u. every other day) resulted in complete tumor regression in five of seven mice. In contrast, single or multiple injections of control vector Luc-ADV did not significantly alter tumor xenograft outcome. Ribozyme expression was confirmed in H441 cells that demonstrated reduced growth after KRbz-ADV treatment. Reduced growth corresponded to significantly lowered levels of K-ras mRNA, as defined by RT-PCR (51% of untreated level, n = 3) and RNase protection assay (56% of untreated level, n = 4) analyses. Further, 37.5% of KRbz-ADV-treated cells underwent apoptosis, as compared with 11.7%, and 19.0% in untreated and Luc-ADV-treated cultures, respectively. A significantly higher proportion of KRbz-ADV-treated H441 cells (58.2%) underwent apoptosis when maintained under anchor-independent conditions that simulate in vivo tumorigenesis ('anoikis'). This is the first report that demonstrates that KRbz-ADV can effectively inhibit in vivo tumorigenesis, and produces regression of pre-existing human lung tumor xenografts having the relevant K-ras mutation. Gene Therapy (2000) 7, 2041-2050.
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ras that constitutively activates nuclear oncogene products. The Ras signaling process involves the activation of Raf/MAP kinase, as well as multiple effectors including phosphatidylinositiol-3 kinase and the Rho family proteins (Rac/Rho).
1,2 Mutant Ras may contribute to malignant transformation via its multiple roles in cell differentiation and cell cycle regulation, in apoptosis modulation, in reactive oxygen species superoxide generation, and in tumor angiogenesis. [3] [4] [5] [6] Recently, Hahn and coworkers 7 demonstrated that mutation in the H-ras gene is pivotal for tumorigenesis of normal human epithelial and mesenchymal cells. Ras mutation also appears essential for maintenance of the malignantly transformed state. 8 Ras oncogene mutation is one of the most common oncogenetic defects in human cancers. Approximately 30% of lung adenocarcinomas, and 15-20% of all non-small cell lung cancers (NSCLC) carry ras mutations, which portend a poor prognosis for both early and late stage disease. 9 The mutant ras gene is an attractive candidate for lung cancer gene therapy in view of its relatively high mutation rate and restricted localization of point mutations. Indeed, blockage of Ras function at the protein and RNA level produced an anti-tumor effect. [10] [11] [12] The down-regulation of mutant p21 ras correspondingly decreased lung tumor growth in vitro and in vivo. 10 A Kras antisense retroviral construct against the homozygous K-ras codon 61 mutated sequence similarly inhibited the growth of the human lung cancer line H460a in vitro and in vivo. 11, 12 Ribozymes (catalytic RNAs, RNA enzymes) are RNAs with site-specific RNA cleavage or ligation activities. 13, 14 Ribozymes directed at oncogenes (c-fos, BCR-ABL) or the human immunodeficiency virus type 1 were more effective than their antisense counterpart in terms of target mRNA reduction and biologic efficacy. 15 In human tumor models, treatment with a hammerhead ribozyme against the H-ras codon 12 mutation (GGC → GUC) inhibited tumor cell growth in vitro, and partially reverted the malignant phenotype of human bladder carcinoma and melanoma and murine NIH3T3 cells expressing the relevant H-ras mutation. [16] [17] [18] Similarly, anti-K-ras ribozyme targeting the codon 12 mutation (GGU → GUU) inhibited human pancreatic cancer cell growth in vitro, and specifically cleaved mutant but not wild-type K-ras mRNA. 19, 20 By comparison, the applicability of K-ras-specific ribozymes against human non-small cell lung cancers has not been characterized. We recently examined the NSCLC growth-modulating effect of an anti-K-ras codon 12 (GUU) hammerhead ribozyme, since K-ras mutations account for 90% of all NSCLC ras mutations, and 85% of K-ras mutations involve codon 12. We constructed a KRbz adenoviral vector (KRbz-ADV) by homologous recombination of the pACCMVpLpA-KRbz shuttle vector with the pJM17 adenoviral vector. Experiments were carried out using the human lung adenocarcinoma cell line H441 and H1725 that express a heterozygous K-ras codon 12 mutation of GGT → GTT. This report characterizes the tumor growth inhibitory properties of the KRbz-ADV in vitro and in vivo.
Results
Characterization of KRbz-ADV anti-tumor effect in vitro Our KRbz-ADV construct contains a hammerhead ribozyme sequence insert that targets K-ras codon 12 with a GTT mutation. 19, 21 Its antitumor efficacy was evaluated with the NSCLC cell lines H441 and H1725 cells. Both lines have a heterozygous K-ras codon 12 GGT/GTT phenotype as defined by DNA sequencing. 22 KRbz-ADV at 25 p.f.u. per cell significantly inhibited H441 cell growth in vitro in a time-dependent manner, as defined by 3 H-thymidine uptake analysis. There was no significant inhibition at 24 h, whereas H441 growth was reduced by 39 ± 7% (mean ± s.d.; P Ͻ 0.05) at 72 h (Figure 1) , and corresponded to a 31% reduction in viable cell number as defined by trypan blue exclusion analysis. Growth inhibition at 96 h was more pronounced than the observed effect at 72 h (data not shown). KRbz-ADV treatment similarly reduced Growth inhibition was increased following treatment with a higher dose (100 p.f.u. per cell; reduction of 63 ± 5% and 94 ± 3% for H441, H1725 cells, respectively). To further correlate antitumor effect with K-ras ribozyme function, parallel studies were carried out with a mutant anti-K-ras ribozyme adenoviral vector (mutKRbz-ADV) that has the same specificity as KRbz-ADV, but lacks ribozyme catalytic activity. MutKRbz-ADV produced only moderate growth inhibition (15 ± 14% and 16 ± 5% for H441 and H1725 cells, respectively) that was significantly lower than that by KRbz-ADV (Figure 1 ). These findings indicate that KRbz-ADV inhibited the in vitro growth of NSCLC cells with the relevant K-ras mutation, and effective inhibition was dependent on the catalytic cleavage activities of the K-ras ribozyme.
For H441 cells, there was no significant growth reduction in H441 cultures following treatment with comparable doses of a control adenoviral vector containing the luciferase gene insert (Luc-ADV; 4 ± 14%; P Ͻ 0.05; Figure 1 ). At an MOI of 5 p.f.u. per cell, only KRbz-ADV significantly inhibited the growth of H1725 cells (24.6 ± 3.9%; versus 2.0 ± 2.4% by Luc-ADV, and −2.0 ± 10.5% by mutKRbz-ADV). At an MOI of 25 p.f.u. per cell, KRbz-ADV inhibited H1725 growth by 71 ± 3.1% (Figure 1 ), although this growth inhibitory effect may be partially attributed to a higher sensitivity of this cell line to the ADV infection process: Luc-ADV also inhibited H1725 growth, albeit at a significantly lower level (39 ± 2.8%, Figure 1 ).
The selective growth inhibitory effect of KRbz-ADV was further confirmed with the NSCLC cell line H1650 having a wild-type K-ras phenotype, as well as with a primary culture of normal human bronchial epithelium (NHBE) cells. KRbz-ADV did not significantly inhibit the growth inhibition of H1650 cells (12. Effect of KRbz-ADV on K-ras expression We examined K-ras mRNA levels to identify the contribution of K-ras cleavage in the KRbz-ADV-mediated antitumor effect. Two sets of RT-PCR reactions were used to establish the level of uncleaved K-ras mRNA (product I) and total of (uncleaved + cleaved) K-ras mRNA (product II). Product I spans the second nucleotide of exon 1 to the 62nd nucleotide of exon 2, lapses the potential KRbz cleavage site at codon 12 (GUU; Figure 2a) , and corresponds to full length K-ras mRNA. Its level is expected to be decreased upon cleavage of mutant K-ras mRNA. Product II spans the 56th nucleotide of exon 1 to the 62nd nucleotide of exon 2, and reflects total (KRbz-cleaved and uncleaved) K-ras mRNA, since the 3′ fragment of KRbzcleaved K-ras mRNA still serves as a viable template for product II amplification. The molecular identity of product I and II was verified by automated DNA sequencing. There were approximately equal proportions of wild-type and mutant K-ras mRNA in untreated H441 MOI, multiplicity of infection; NHBE, normal human bronchial epithelium. a Cell cultures were infected by LacZ-ADV vector at 1-100 p.f.u. per cell and stained by the X-gal assay at 72 h after infection (see Materials and methods). The percentage of transduced cells versus total cell number was estimated by light microscopy enumeration of X-gal-stained cells versus total cells.
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Figure 2 RT-PCR analysis of K-ras mRNA expression. RT-PCR analysis of uncleaved (product I) and total (cleaved + uncleaved; product II) K-ras mRNA was carried out using K-ras specific primers with concomitant amplification of ␤-actin mRNA. (a) Schematic representation of K-ras specific primer locations (P1, P2 and P3) with respect to K-ras mRNA. (b) RT-PCR amplification products (K-ras 32 cycles; ␤-actin: 25 cycles) as revealed by electrophoresis on 2% agarose gel with ethidium bromide staining. Lanes 1 and 4, untreated H441 cells; lanes 2 and 5, KRbz-ADVtreated H441 cells; lanes 3 and 6, Luc-ADV-treated H441 cells. (c) Relative levels (mean % ± s.e.m.) of K-ras mRNA as compared with untreated cultures, as determined by densitometric analysis of RT-PCR products (see Materials and methods).
cells, based on peak height analysis of product I DNA sequences. KRbz-ADV treatment manifested as a reduction of full length K-ras mRNA (product I) (49 ± 3.2%, n = 3; P Ͻ 0.05; Figure 2 ), whereas Luc-ADV treatment did not significantly alter the level of intact K-ras mRNA. Total K-ras mRNA level was reduced moderately following KRbz-ADV treatment (19 ± 4.6% decrease in product II). The reduction in functional full length K-ras mRNA is consistent with the KRbz ribozyme cleavage effect at the posttranscriptional level. 23 Ribonuclease protection assay (RPA) analysis similarly confirmed that KRbz-ADV reduced K-ras mRNA expression (44 ± 13.3%, n = 4; P Ͻ 0.05) as compared with untreated cultures (Figure 3 ). By contrast, mutKRbz-ADV treatment did not significantly reduce K-ras mRNA levels (0 ± 8.8%, n = 4; P Ͼ 0.05). These findings support the thesis that growth inhibition by KRbz-ADV correspondingly lowers the level of K-ras mRNA, an outcome that is dependent on the catalytic cleavage activity of the K-ras ribozyme.
Ribozyme expression in cells that exhibited the relevant growth inhibitory effect was verified by RPA ( Figure 3 ) and RT-PCR (data not shown) analyses. The relative molar ratio of ribozyme versus K-ras mRNA was 
-actin (c), and RNA extracts from untreated H441 cells (lane 2) or cells treated by KRbz-ADV (lane 3), control Luc-ADV (lane 4) or mutKRbz-ADV (lane 5) for 72 h (100 p.f.u. per cell). Lane 1, corresponding full-length probes for KRbz (327 bases), K-ras (198 bases) and ␤-actin (275 bases). Arrows indicate the expected positions for the intact full-length probes and their RNA-protected fragments (20 bases shorter), based on migration distance of concurrently resolved RNA size markers (not shown).
determined to be 1.55:1, based on gel band densitometric analysis of ribonuclease-protected products in KRbz-ADV infected H441 cells (100 p.f.u. per cell). These findings are consistent with observations that ribozyme:targeted RNA ratios of Ͼ1 are needed for effective substrate cleavage. 11 tested, data not shown). KRbz-ADV treatment (у10 p.f.u. per cell) completely abrogated H441 tumor xenograft growth in nu/nu mice (n = 13; Figure 4 ). The lack of tumor growth at the site of injection was confirmed by histological evaluations at the end of observation period. By contrast, pre-treatment with mutKRbz-ADV did not affect H441 tumor take or growth (n = 4), as compared with untreated mice (Figure 4) .
Similarly, mice inoculated with same number of KRbz-ADV-pretreated H1725 cells did not produce tumor xenografts for up to 90 days (n = 8), whereas untreated H1725 tumors grew exponentially within 2-3 weeks with a 100% tumor take. These findings indicate that KRbz-ADV inhibited the in vivo tumorigenesis of NSCLC H441 and H1725 cell xenografts, and this effect was dependent on the catalytic cleavage activity of KRbz-ADV.
Parallel Luc-ADV treatments were carried out to characterize specificity of the KRbz-ADV growth inhibitory effect. Luc-ADV at 10 p.f.u. per cell did not inhibit H441 heterotransplants, which grew at the same rate as untreated tumor xenografts ( Figure 4 ). Treatment with a higher dose of Luc-ADV (20 or 50 p.f.u. per cell) retarded growth and delayed tumor emergence (palpable at day 35, as compared with 14-21 days for untreated inoculants; Figure 4 ), although its growth inhibitory effect was significantly lower than the corresponding dose of KRbz-ADV. No overt metastatic growth was detected in the major organs (lung, liver, spleen, kidney, heart and peritoneal membranes) of mice that received untreated, or KRbz-ADV pre-treated H1725 or H441 cells at day 60-90 after inoculation. Gross toxicity (loss of activities, body weight) was not evident for either KRbz-ADV or Luc-ADV-treated mice.
To characterize better the clinical applicability of KRbz-ADV treatment on pre-existing tumors, intratumoral injections were initiated at day 7 after tumor induction. For H441 xenografts, a single intratumoral injection (2 × 10 9 p.f.u.) significantly reduced the primary tumor size by 39% (6.04 ± 1.09 mm at day 21, n = 7; P = 0.0061) as compared with untreated mice (9.86 ± 2.84 mm, n = 7), but did not completely inhibit tumor xenograft growth as observed in pretreatment studies (Figure 4) . One reason may be that the viral transduction process in vivo is less efficient than that in vitro. By comparison, multiple KRbz-ADV intratumoral injections (2 × 10 9 p.f.u. every other day) can completely inhibit pre-existing tumor growth (Table 2 ). Only two of seven animals that received three or five KRbz-ADV injections continued to have tumor growth. This represents a significantly decreased incidence (P Ͻ 0.05) as compared with untreated or mock treated groups (Table 2) . Further, tumor size of the two remaining tumor-bearing mice was reduced markedly (tumor diameter of 9.15 mm in one mouse after three KRbz-ADV injections; 7.60 mm in one mouse after five KRbz-ADV injections, versus 13.19 ± 1.0 mm in six of six untreated mice at day 42 after tumor inoculation). One animal had complete tumor regression after five repeat Luc-ADV injections, which may be attributable to the non-specific growth inhibitory effect of ADV infection. 26 However, single or multiple control Luc-ADV injections did not significantly alter tumor xenograft outcome (P Ͼ 0.05). Our findings demonstrate that multiple treatments with KRbz-ADV are effective in inducing NSCLC tumor regression in vivo. 
Induction of apoptosis on NSCLC cells by KRbz-ADV
To explore cellular mechanisms that contribute to the KRbz-ADV growth inhibitory effect, we examined the level of apoptosis in KRbz-ADV-treated H441 cells by vital dye (7-AAD) uptake. 27, 28 The percentage apoptotic cells in KRbz-ADV-treated H441 cultures was significantly elevated (37.5%, P Ͻ 0.01) as compared with untreated (11.7%) and control-vector treated (19.0%) cultures (Table 3) . KRbz-induced apoptosis was further increased (58.2%) under anchor-independent growth conditions, and was significantly higher than that in KRbztreated adherent cultures (P Ͻ 0.05, Table 3 ). By comparison, apoptotic activities did not differ significantly among adherent and non-adherent cultures for untreated (P Ͼ 0.05) or Luc-ADV-treated cells (P Ͼ 0.05; Table 3 ). ) under anchor-independent culture conditions and 33% in adherent cultures. Our findings demonstrate that KRbz-ADV treatment significantly up-regulated apoptotic activity, an effect that was augmented under anchor-independent culture conditions that simulate in vivo anti-tumorigenesis. Gene Therapy
Discussion
In vitro and in vivo antitumor outcome through inhibition of mutant K-ras oncogene activity has been demonstrated with Ras neutralizing antibodies and anti-K-ras antisenseplasmids or retroviral-constructs. 11, 12, 29, 30 Another alternative for targeting the ras mutant gene is by the anti-ras ribozyme construct, which provides theoretical stoichiometric advantage over its antisense counterpart and may be delivered as a viral construct for improved pharmacokinetics. 14 Rbzs targeting mutant H-ras and K-ras sequence have been shown to inhibit the growth of human bladder, melanoma and pancreatic carcinomas. 16, 17, 19 However, there is limited information regarding the efficacy of KRbz on NSCLC tumors expressing K-ras codon 12 mutations, despite prevailing observations that Ͻ85% of NSCLC ras mutations reside at K-ras codon 12. 9, 31 In this study, we have examined the in vitro and in vivo growth inhibitory effects on NSCLCs by KRbz, and its antitumor mechanism of action. H441 and H1725 cells, both having a single point mutation (GGT → GTT) in one of the K-ras codon 12 alleles, are expected to reflect the heterozygous ras status in most NSCLC patient tumors. These cell lines were used to examine the antitumor effect of a hammerhead ribozyme designed to cleave the GUU sequence in codon 12 of the activated K-ras mRNA transcript, one of most prevalent ras mutations in human lung cancer.
9,31 A KRbz-ADV viral construct was generated, since ADV vectors are capable of infecting most dividing and non-dividing cells with a high efficiency of gene transfer, and are obtainable in high titers. 32 In light of its natural tropism for respiratory tissues, the adenovirus vector is particularly appropriate for anti-tumor gene delivery to lung cancer. The efficacy of this KRbz-ADV construct was confirmed by its capacity to inhibit H441 and H1725 cell growth by up to 94% in vitro. Therapeutic efficacy of KRbz-ADV was supported by our in vivo findings that KRbz-ADV abrogated tumorigenesis, reduced pre-existing tumor xenograft growth, and induced complete tumor regression in up to 75% of mice after repeat intratumoral KRbz-ADV injections. These findings are consistent with an essential role of mutant Ras in tumorigenesis and lung tumor maintenance. 8 Certain anti-ras approaches such as farnesyltransferase inhibitors are more effective against tumors with H-ras mutations. 33, 34 Our study indicates that the appropriate Rbz appears to be equally effective against tumors with H-ras or K-ras mutations. This consideration is particularly significant, in view of the prevalence of K-ras mutant human solid cancers. 35 Our report represents the first documentation of in vivo antitumor efficacy by a Kras ribozyme against human lung tumors with the relevant mutation.
Specificity of KRbz-ADV mediated tumor-growth inhibition is validated by our current findings of its selective toxicity on H441 cells. H1725 cells appeared to be sensitive to ADV infection. Nevertheless, KRbz-ADV produced significantly higher growth inhibition, as compared with the control Luc-ADV vector. We previously showed that this KRbz, when delivered as a plasmid, inhibited the in vitro growth of H1725 cells by up to 82% without any cytotoxic effect on NSCLC H460 cells lacking the relevant K-ras mutation. 22, 36 The same KRbz-plasmid was found to reduce selectively pancreatic cancer K-ras mRNA level without affecting control cells having an irrelevant mutation. 20 Conversely, our KRbz-ADV produced a minimal growth inhibitory effect on NSCLC H1650 cells and normal human bronchial epithelial cells with a wild-type Kras phenotype. In our xenograft model, intratumoral KRbz-ADV injections produced no gross toxicity (loss of activities, body weight) or overt toxicity in major organs of mice. These findings indicate that such an adenoviral construct at Ͻ1 × 10 10 p.f.u. may be safely administered in vivo [37] [38] [39] Similarly, the Ad5CMV-p53 adenovirus, which shares a similar adenoviral construct as KRbz-ADV, produced only mild to moderate acute toxicity when given intratracheally at 10 10 p.f.u. 39 The in vitro KRbz-ADV anti-tumor effect correlated with an approximately 50% decrease in full length K-ras mRNA transcripts, suggesting that the down-regulation of ras expression may be involved in tumor growth inhibition. Previously, we have reported that KRbz-ADV collaterally decreased mutant p21 Ras protein levels. 36 For this study, the significant down-regulation of full length K-ras (product I) is consistent with the expected cleavage activity of KRbz. 23 The approximate 50% reduction in product I was confirmed by RT-PCR and subsequent RPA analyses. A moderate decrease in the total (cleaved and intact) K-ras mRNA (product II) may be attributable to subsequent degradation of KRbz-cleaved mRNA by RNase L. 40 For H441 cells with a heterozygous ras phenotype, we found that both the wild-type and mutant Kras genes were co-expressed at a comparable level. An incomplete reduction in ras mRNA expression is consistent with the premise that KRbz-ADV does not act on wild-type K-ras. Our findings support prior observations that tumor cells appear to be more dependent on mutant ras function, 41 such that a less than complete reduction of activated ras expression could nevertheless significantly affect tumor cell growth.
The experimental characterization of K-ras mRNA levels required RNA extraction from KRbz-ADV-infected cells, RNA reverse transcription and RNA hybridization processes during RT-PCR and RPA analyses. Although theoretically possible, it is unlikely that the observed down-regulation of K-ras mRNA represented the outcome of cell-free cleavage by KRbz during these procedures. RNA isolation was performed primarily at 4°C in less than 2 h. In vitro cell-free ribozyme-dependent substrate cleavage requires stringent conditions, including high pH (у7.5), optimized temperature (у37°C), extended incubation (usually у18 h) and the presence of magnesium (у1 mm). 24, 25, 42 These requirements were inconsistent with our conditions for RT-PCR. RPA did not require any divalent metal ions during RNA hybridization reaction or a RNA transcription step but nevertheless demonstrated that KRbz-ADV reduced Kras mRNA expression by 50% (Figure 3 ). MutKRbz-ADV did not produce significantly altered K-ras mRNA under the same RPA conditions. Thus it is unlikely that the decreased level of K-ras mRNA represented experimental artifacts.
Activated Ras has been shown to play an important role in tumor cell proliferation, differentiation, in vivo cell attachment/survival and angiogensis. Our thesis of a KRbz-dependent growth inhibitory phenomenon is supported by the findings that only KRbz-ADV was effective in inhibiting xenograft growth, whereas comparable doses of Luc-ADV did not. It is not fully understood as to why KRbz-mediated growth inhibition was more pronounced in vivo. Recent studies suggest that antisensesuppression of activated ras increases apoptosis. 43 Mutant ras is particularly effective in nullifying 'anoikis', an apoptotic event that comes into play when cells become detached from an underlying extracellular matrix. 3, 5 Similarly, we found that KRbz-ADV treatment was 50% more effective in inducing apoptosis (from 37.5% to 58.2%) under anchor-independent culture conditions that simulate in vivo tumorigenesis. This may explain, at least in part, the more dramatic growth inhibitory effect of KRbz-ADV in vivo. Future studies are needed to evaluate other potential contributing mechanisms, such as anti-angiogenic and cell cycle regulatory events that may also manifest as 'bystander effect' on neighboring untransfected tumor cells. 6, 44, 45 Recent clinical trials have utilized the selective adenoviral cytopathic effect by targeting p53 deficient cancer cells with E1B defective adenoviruses, since cells with normal p53 are more resistant (100-fold) to viral lysis. 46 NSCLC H1725 cells have a wt p53 gene, whereas H441 cells have a point mutation in exon 5 of p53 gene. 47 Nevertheless, we observed significantly higher growth inhibition in wt p53 H1725 cells by KRbz-ADV. Thus the selective adenoviral oncolytic effect on p53-deficient cells appears not to be the dominant factor for the antitumor outcome of KRbz-ADV.
Our studies demonstrated that KRbz-ADV is effective for in vitro and in vivo growth inhibition of NSCLCs. The potential clinical applicability of KRbz-ADV treatment is supported by our findings that a single intratumoral injection was effective in reducing tumor growth by Ͼ35%, and that multiple intratumoral injections of KRbz-ADV produced complete xenograft regression in 65-75% of animals. Further analyses are planned to determine the anti-tumor effect of systemic KRbz-ADV treatment. Despite the limited proportion of lung cancers eligible for treatment by each Rbz, the ribozyme adenoviral vector approach is nevertheless potentially applicable because of the considerable incidence of human lung cancers. Upon demonstration of clinical efficacy, it is not inconceivable that multiple individual ribozymes can be generated, each targeting a specific K-ras mutation. In parallel with current clinical trials on p53-ADV or E1B defective ADV, the use of KRbz-ADV represents another gene therapy approach potentially applicable to the treatment of lung cancers.
Materials and methods
Cells NSCLC cell lines NCI H441 (adenocarcinoma) and H1725 (large cell carcinoma) were kindly provided by Dr Herbert Oie (National Cancer Institute, Bethesda, MD, USA). The NSCLC cell line H1650 (adenocarcinoma with wt Kras) was obtained from the American Type Culture Collection, Rockville, MD, USA. 48 These cell lines were cultured in T75 flasks in RPMI 1640 (Gibco/BRL) and 10% fetal bovine serum (FBS; Atlanta Biological, Atlanta, GA, USA). The low-passage transformed human embryonic kidney cell line 293 was obtained from American Type Culture Collection, and cultured in Dulbecco's modified Eagle's medium supplemented with 10% heat-inactivated horse serum and penicillin-streptomycin (Gibco, Grand Island, NY, USA). Primary cultures of normal human bronchial epithelium (NHBE) cells were purchased from BioWhittaker/Clonetics (Walkersville, MD, USA) and maintained according to the manufacturer's recommendations in optimized growth medium (SABM and SAGM, BioWhittaker/Clonetics).
Generation of the anti-K-ras ribozyme adenoviral vector (KRbz-ADV) The K-ras ribozyme was prepared as described previously. 21 An E1-deleted, replication defective adenoviral vector containing anti-K-ras ribozyme insert (KRbz-ADV) was constructed by homologous recombination of the adenoviral shuttle vector pACCMVpLpA-KRbz and the packaging plasmid pJM17. pACCMVpLpA plasmids with the anti-K-ras ribozyme insert were co-transfected with pJM17 into the E1A trans-complementing cell line 293, using the commercial cationic liposome vector DOTAP (Boehringer-Mannheim, Mannheim, Germany). 21 A mutant anti-K-ras ribozyme-adenoviral vector (mutKRbz-ADV), which contains a single residue replacement (G to A) in the catalytic core with respect to KRbz-ADV construct, shares the same specificity as KRbz-ADV but lacks ribozyme function. 49 Adenoviral vector that contained the Escherichia coli ␤-galactosidase gene (LacZ-ADV) was also constructed in a similar manner. 26 The primary recombinant adenovirus stock was clonally selected three times by standard 293 cell plaqueforming assays. 50, 51 Recombinant adenoviruses contain the correct ribozyme insert and are free of detectable wild-type adenovirus, as defined by appropriate PCR assays. 36, 52 The recombinant adenoviruses were prepared by two rounds of CsCl gradient centrifugation and titered in 293 cells. 50, 51 The corresponding ADV vector with a luciferase gene insert (Luc-ADV) was obtained from Dr Stephen A Johnston, University of Texas Southwestern Medical Center, Dallas, TX, USA. This control vector has a similar structural configuration as the KRbz-ADV vector except for the luciferase gene insert at multiple cloning sites. Reverse transcription (RT)-PCR assay and ribonuclease protection assay (RPA) Subconfluent H441 cells (4.5 × 10 6 ) were infected with the appropriate ADV vector at 100 p.f.u. per cell, then cultured for 72 h. Total RNA was isolated with TRIZOL reagents according to manufacturer's protocol (Gibco). RT-PCR assays were carried out using GeneAmp PCR System 2400 thermal cycler and GeneAmp RNA PCR kit (Perkin Elmer, Norwalk, CT, USA) as described previously with modifications. 55 To quantify the level of Kras mRNA, co-amplification of K-ras mRNA and an internal control message (␤-actin) was carried out in the same reaction mixture for both RT and PCR steps. Three g of total RNA template were co-annealed with the KrasP2 primer and/or ␤-actinP2 primer (50 ng each, 45 min 55°C). Reverse transcription (20 l) was carried out with 6 l of the annealing mixture (1 hr, 42°C). The cDNA products were amplified by standard PCR (94°C, 45 s; 55°C, 30 s; 72°C, 45 s; 32 cycles). The use of K-rasP1 primer and K-rasP2 primer generates a cDNA product only from the uncleaved K-ras mRNA (RT-PCR product I, 172 bp). The K-rasP3 primer and K-rasP2 primer were used to generate a cDNA product corresponding to the KRbz-cleaved sequence, thereby identifying total (both uncleaved and cleaved) K-ras mRNA (RT-PCR product II, 118 bp). The ␤-actinP1 and P2 primers were added into each PCR reaction mixture after seven PCR cycles in order to balance the final yields of ␤-actin (249 bp) and K-ras product. The K-ras RT-PCR products were confirmed by DNA sequencing (Big Dye Terminator method, ABI 310 Automated DNA Sequencer; Perkin Elmer). Changes in the levels of K-ras intact and cleaved mRNA (product I and product II) were determined by densitometric analysis following normalization to the corresponding ␤-actin value, which serves as the internal standard in semi-quantitative RT-PCR analysis (AlphaImager 2000 D, Alpha Innotech, San Leandro, CA, USA; and Scion Image Software, Scion, Frederick, MD, USA). Mean ± s.e.m. were determined by averaging the data from a minmum of three separate experiments.
mRNA were extracted from total RNA using the Oligotex mRNA Mini-agents (Qiagen, Valencia, CA, USA) according to manufacturer's protocol. 0.1-0.3 g mRNA was screened for anti-K-ras ribozyme expression by stan- (14-16 h) . Gel band densitometric analysis was performed as described above for RT-PCR assays. The level of ribozyme expression relative to K-ras mRNA was expressed as a molar ratio by comparing the optical density for their representative gel bands normalized to housekeeping ␤-actin mRNA (an internal standard), and adjusted for molecular sizes.
The sequence for the primers used in RT-PCR and RPA studies were the following: K-rasP1 primer: 5′-GACTGAATATAAACTTGTGG-3′; K-rasP2 primer: 5′-GTGTCGAGAATATCCAAGAG-3′; K-rasP3 primer: 5′-TGACGATACAGCTAATTCAG-3′; K-rasP4 primer: 5′-TAATTAAATAATATAATAAT GACTGAATATAAACTTGTGG-3′; K-rasP5 primer: 5′-AATACGACTCACTATAGGGAGG GTGTCGAGAATATCCAAGAG-3′; KRbzP1 primer: 5′-GCGTGACGGTGGGAGGTCT-3′; KRbzP2 primer: 5′-GTTTCGTCCTCACGGACTCAT-3′; KRbzP3 primer: 5′-TTGGGACTGTGAATCTAAAAT-3′; KRbzP4 primer: 5′-TAATTAAATAATATAATAATGC GTGACGGTGGGAGGTCT-3′; KRbzP5 primer: 5′-AATACGACTCACTATAGGGAGG TTGGGACTGTGAATCTAAAAT-3′; ␤-actinP1 primer: 5′-TACGCCAACACAGTGCTGTCT-3′; ␤-actinP2 primer: 5′-CTAGAAGCATTTGCGGTGGAC-3′; ␤-actinP3 primer: 5′-TAATTAAATAATATAATAATT ACGCCAACACAGTGCTGTCT-3′; ␤-actinP4 primer: 5′-AATACGACTCACTATAGGGAG GCTAGAAGCATTTGCGGTGGAC-3′.
NSCLC cell line heterotransplantation
To determine optimal engraftment conditions, 1-10 × 10 6 H1725 cells were injected subcutaneously (s.c.) into 4-6-week-old female NIH Swiss nude mice (NIHS-nufDF, Taconic Farm, Gaithersberg, MD, USA). Tumor engraftment was not evident in mice that received s.c. inoculation of 1 × 10 6 cells for a period of 90 days afterinjection. In contrast, all the mice that received 1 × 10 7 H1725 cells developed palpable tumor xenografts that grew progressively at 2-4 weeks after inoculation. H441 xenograft nodules (inoculation of 1 × 10 7 cells) were measurable at day 7, and these tumor xenografts grew progressively from 2 weeks after tumor inoculation.
DNA from tumor xenograft (but not mouse lung tissue) expressed the human K-ras sequence including the K-ras codon 12 GTT/GGT heterozygous mutation of the parental cell line, as defined by PCR. There was Ͼ95% tumor take in mice that received 1 × 10 7 H1725 or H441 cells under optimized conditions. To study the antitumorigenic effect of KRbz treatment, subconfluent H1725 cells or H441 cells were either untreated, or infected with KRbz-ADV, mutKRbz-ADV or Luc-ADV (10 to 20 p.f.u. per cell, 20-24 h) before injecting into mice (s.c., 1 × 10 7 cells in 0.1 ml RPMI 1640). 51 The mice were observed twice weekly for tumor emergence. Palpable xenografts were measured by a vernier caliper twice a week for up to 42 days. Tumor size was expressed as the mean tumor diameter, based on the geometric mean of two perpendicular measurements. Animals were killed when the tumor xenograft exceeded 3 cm in diameter or at the end of experimental period of up to 60 days, whichever comes first. For treatment of pre-existing s.c. H441 xenografts, animals received single or multiple (three or five) intratumoral injections of KRbz-ADV or control Luc-ADV (2 × 10 9 p.f.u. in 0.1 ml), or medium only, every other day starting at day 7 after tumor inoculation. All procedures involving animal use were approved by the Institutional Animal Care and Use Committee at Baylor University Medical Center. Differences in primary tumor xenograft size were compared statistically using the twotailed Student's t test. Frequency of animals with posttreatment tumor regression was compared by the Fisher's exact two-sided test.
Analysis of apoptotic activity
The level of apoptosis induced by KRbz-ADV was determined by flow cytometric analysis following 7-amino actinomycin D (7-AAD) or annexin V and propidium iodide (PI) staining (FACScan, Becton Dickinson). Subconfluent cultures were infected with either KRbz-ADV or Luc-ADV vector (50 p.f.u. per cell, 20-24 h). The cells were trypsinized, then replated for 48 h (1 × 10 6 cells per dish) in 60-mm standard culture dishes or polyHEMA-treated culture dishes (Sigma) that prevent
